Thus, we suggested short-term therapy (about 8 days) of 2MIU IL2 injection would provide potent clinical benefit for ALS patients, and long-term treatment (about 64 days) of 1MIU IL2 injection may as well be beneficial. The gene discussed is IL2; the disease is amyotrophic lateral sclerosis.